GLP-2 analogue

Teduglutide

Brand names: Revestive

Teduglutide is a glucagon-like peptide-2 analogue used to treat short bowel syndrome in patients dependent on parenteral support, under specialist supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

As a GLP-2 analogue it promotes growth and improves the absorptive function of the intestinal mucosa, increasing fluid and nutrient absorption.

Prescribing in practice

Because it is trophic to intestinal tissue, colonoscopy to exclude colonic polyps or neoplasia is required before starting and periodically during treatment.
It can cause intestinal obstruction and worsen fluid overload, and may increase the absorption of concomitant oral medicines, requiring their review.
Treatment should be initiated and monitored within a specialist intestinal failure service.

Monitoring

Perform colonoscopic surveillance per the SPC and monitor fluid balance, nutritional status, and parenteral support requirements.

Counselling the patient

Attend all scheduled colonoscopies and monitoring appointments.
Report abdominal swelling, persistent vomiting, or marked changes in your stoma or bowel output.

Evidence & guidelines

Teduglutide is recommended for short bowel syndrome to reduce dependence on parenteral nutrition in selected patients.

Reference: NICE HST12; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Curated clinical cross-links plus same-class fallbacks.

Pathways